NTLA Stock — Intellia Therapeutics Inc.: Cash, EV, Pipeline

What they do

Our mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, we aim to reset the standard for medicine by durably treating the root causes of disease.

Source: 10-K FY2025 via SEC EDGAR

Share price

$11.35

Market cap

$1,590.4M

Cash

$614.8M

Enterprise value

$1,049.3M

Balance sheet

Cash	$614.8M
Debt	$73.7M
Net cash	$541.1M
Enterprise value	$1,049.3M
Basic shares	140.4M shares
Fully diluted shares	160.8M shares
Fully diluted market cap	$1,824.7M
Cash per share	$4.38
Quarterly burn	$83.1M
Cash runway	5.3 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common

114.2M

Pre-funded warrants

0.0M

Options

24.9M

RSUs

21.7M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

0.0M

FDSO

160.8M

Cap table as of 2026-07-31.

Price history

Loading NTLA daily closes…

Loading price history…

Next catalyst

lonvoguran ziclumeran (NTLA-2002) · Mar 10, 2027 · guided in 4 mo

Recently reported

lonvo-z Phase 3 Positive · 2026-04-27

HAELO · hereditary angioedema

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDMar 10, 2027 in 4 mo	lonvoguran ziclumeran (NTLA-2002) lonvo-z BLA PDUFA for hereditary angioedema	Not disclosed	hereditary angioedema	March 10, 2027
Aug 12 - Sep 23 in 9 mo	nexiguran ziclumeran	Phase 3	Neuromuscular Disease; Neuromuscular Diseases (NMD); Neurodegenerative Disease	—
Jan 12 - Feb 23 in 14 mo	NTLA-2001	Phase 3	Transthyretin Amyloidosis (ATTR) With Cardiomyopathy	—
Sep 25 - Nov 6 in 96 mo	REGV131	Phase 1/2	Hemophilia B	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

lonvo-z

Phase 3 · Active Modality: in vivo CRISPR-based gene editing therapeutic

Aliases lonvoguran ziclumeran, NTLA-2002

Target kallikrein B1 (KLKB1)

Partnerships Wholly owned.

Indications

Hereditary angioedema (HAE) (Phase 3)

Catalysts

— 2H 2026
— 1H 2027

Status note Wholly-owned investigational in vivo CRISPR therapeutic for HAE (inactivates the KLKB1 gene in the liver) delivered as a single IV infusion. Positive topline data from the global Phase 3 HAELO trial reported Apr 2026. Rolling BLA initiated Apr 2026; launch readiness activities underway.

nex-z

Phase 3 · Active Modality: in vivo CRISPR-based gene editing therapeutic

Aliases nexiguran ziclumeran, NTLA-2001

Target transthyretin (TTR)

Partnerships Co-development and co-promotion (Co/Co) agreement with Regeneron Pharmaceuticals for ATTR amyloidosis (2018). License and other agreements include up to $130M in contingent payments to Rewrite Therapeutics.

Indications

Transthyretin (ATTR) amyloidosis (Phase 3)

Catalysts

— 2H 2026

Status note Investigational in vivo CRISPR therapeutic for ATTR amyloidosis (inactivates the TTR gene in the liver) delivered as a single IV infusion via LNP technology. Phase 3 MAGNITUDE and MAGNITUDE-2 studies ongoing.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	NTLA-2002
Lead indication	Hereditary Angioedema
Lead phase	Phase 3
Active trials	6
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06672237	Phase 3	Recruiting	Sponsor	Intellia Therapeutics	REGN	Neuromuscular Disease; Neuromuscular Diseases (NMD); Neurodegenerative Disease	—
NCT06128629	Phase 3	Recruiting	Sponsor	Intellia Therapeutics	REGN	Transthyretin Amyloidosis (ATTR) With Cardiomyopathy	—
NCT06634420	Phase 3	Active, not recruiting	Sponsor	Intellia Therapeutics	—	Hereditary Angioedema	—
NCT05120830	Phase 1/2	Active, not recruiting	Sponsor	Intellia Therapeutics	—	Hereditary Angioedema	—
NCT05697861	Not disclosed	Enrolling by invitation	Sponsor	Intellia Therapeutics	—	Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy; Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy; Wild-Type Transthyretin Cardiac Amyloidosis	—
NCT06262399	Not disclosed	Enrolling by invitation	Sponsor	Intellia Therapeutics	—	Hereditary Angioedema	March 10, 2027
NCT06379789	Phase 1/2	Recruiting	Collaborator	REGN	REGN	Hemophilia B	—

Sponsor-matched active trials from ClinicalTrials.gov (6 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 7 active trials for Intellia Therapeutics on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
RA Capital Management	4,526,926	+4,526,926	0.67%	2026-08-14
Baker Bros. Advisors	930,232	+930,232	0.08%	2026-08-14
Casdin Capital	355,000	no change	0.30%	2026-08-14
ADAR1 Capital Management	0	-19,517	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

NTLA — Intellia Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

NTLA — Intellia Therapeutics Inc.